Skip to content
Search

Latest Stories

Ipsen obtains development and commercial rights to mesdopetam

Ipsen and IRLAB have signed a licensing agreement, providing Ipsen exclusive worldwide development and commercial rights to mesdopetam, a novel dopamine D3-receptor antagonist.

Mesdopetam is being assessed in Phase IIb clinical trials as a potential treatment option for people living with Parkinson’s disease (PD) experiencing levodopa-induced dyskinesia (LID).


It is estimated that approximately 40-50 per cent of people living with PD will experience LID after five years of initiating dopamine replacement therapy. LID currently has limited treatment options.

Mesdopetam is also in early development for Parkinson’s Disease Psychosis (PDP), which is a common symptom of PD; around 50 per cent of people with PD eventually develop such symptoms over the course of their disease.

PD is a common, progressive neurodegenerative condition affecting more than 10 million people worldwide. PD affects nerve cells in the brain that control movement and affects patients differently; the most common motor symptoms however are tremor, muscle rigidity and slowness of movement. People living with PD also experience other problems not related to movement including anxiety, pain and depression.

Symptoms of PD are most commonly managed by medicines, such as levodopa that aim to compensate for the loss of dopaminergic neurons. A common side effect of levodopa is dyskinesia, involuntary and erratic movements of the face, arms, legs or trunk.

For many people, dyskinesias can be so severe that they interfere with normal functioning. Mesdopetam has also shown antipsychotic properties in preclinical studies.

Dr Howard Mayer, executive vice president and head of R&D, Ipsen, said: “We are excited to enter this licensing agreement with IRLAB. By working in partnership, we aim to bring investigational mesdopetam to people living with Parkinson’s disease experiencing levodopa-induced dyskinesia. We are delighted to strengthen our pipeline and deepen our commitment to the neuroscience community around the world, including to patients living with this debilitating neurodegenerative disorder.”

Dr Nicholas Waters, CEO of IRLAB, said “We believe in the potential of investigational mesdopetam for people with Parkinson’s disease experiencing dyskinesia or psychosis. We have purposefully worked to find a partner to pursue the late-stage clinical development of mesdopetam to commercialization and launch on a global market.

"Ipsen shares the broad vision for mesdopetam and the commitment to people with neurological disorders."

Waters added: "We are very excited to enter the final steps of the journey to market in collaboration with Ipsen. Additionally, we are proud of the accomplishment this important collaboration represents. The agreement and partnership with Ipsen is a validation of our proprietary discovery platform, ISP, and our drug development efforts. This deal is one of

the larger deals struck in the Swedish biotech space in decades, which is a merit for all of us at IRLAB and to those who have supported the mesdopetam project to reach this milestone.”

More For You

MHRA approves Pfizer Hympavzi (marstacimab) for haemophilia treatment

Marstacimab is currently being assessed by NICE and the Scottish Medicines Consortium for use on the NHS

gettyimages

Marstacimab approved for haemophilia treatment, Pfizer aims for NHS availability

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Hympavzi(marstacimab) to prevent or reduce bleeding in patients aged 12 years and older, weighing at least 35kg, who have severe haemophilia A or B.

Developed by Pfizer scientists, this groundbreaking treatment is the first of its kind to target a protein involved in the blood clotting process.

Keep ReadingShow less
​Pope Francis

Pope Francis at the Vatican on December 4, 2024.

Photo by FILIPPO MONTEFORTE/AFP via Getty Images

His Holiness Mahant Swami Maharaj offers condolences to Catholic community following Pope Francis' passing

His Holiness Mahant Swami Maharaj, the spiritual leader and president of the Bochasanwasi Akshar Purushottam Swaminarayan Sanstha (BAPS), has expressed heartfelt condolences to the Catholic community worldwide following the passing of Pope Francis on Monday.

In a formal letter addressed to the members of the Roman Catholic Church, Mahant Swami Maharaj conveyed the deep sorrow of the BAPS Swaminarayan Hindu fellowship, acknowledging the Pope's passing as “a profound loss to the Catholic community and Christians around the world.”

Keep ReadingShow less
Pharmacies in Northern Ireland distribute free booklets to raise cancer awareness

Dr Anna Cullen, Public Health Registrar at the Public Health Agency and Clare Conroy, Community Pharmacist from Meigh Pharmacy in Co Down.

Photo credit: Community Pharmacy Northern Ireland

Pharmacies in Northern Ireland help raise cancer awareness

Community pharmacies across Northern Ireland are distributing a free information booklet to help raise public awareness of the signs and symptoms of cancer and promote early diagnosis.

The initiative is part of the ‘Be Cancer Aware’ campaign, which has been running in pharmacies since April and will continue through May as part of the Living Well service.

Keep ReadingShow less
CPE invites pharmacy owners to share their views on new CPCF funding settlement

What do you think should be the next priority for the Government?

gettyimages

Pharmacy owners asked to share their views on new CPCF arrangements

Community Pharmacy England (CPE) is urging pharmacy owners to share their views on the new Community Pharmacy Contractual Framework (CPCF) funding settlement ahead of its next full Committee meeting, scheduled for 30 April–1 May.

The Committee said it had agreed to the settlement "reluctantly," acknowledging that it represents a significant shift after years of real-terms funding cuts, while admitting that it’s “still not sufficient to match the continued scale of pressures facing pharmacy businesses.”

Keep ReadingShow less
Homecare medicines services face many challenges beyond pharmacy's control

Homecare medicines services face many challenges beyond pharmacy's control

gettyimages

GPhC calls for industry-wide collaboration to strengthen homecare medicines services

The General Pharmaceutical Council (GPhC) has called for industry-wide collaboration to improve homecare medicines services to ensure patients always receive their medicines when needed.

The call follows a recent review by the regulator, which identified several challenges facing homecare services, many of which were beyond the immediate control of the pharmacies providing them.

Keep ReadingShow less